<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551093</url>
  </required_header>
  <id_info>
    <org_study_id>CLP0050613</org_study_id>
    <nct_id>NCT03551093</nct_id>
  </id_info>
  <brief_title>THE IMPACT- 24M TRIAL (IMPlant Augmenting Cerebral Blood Flow in Mild Strokes Trial 24 Hours From Stroke Onset)</brief_title>
  <acronym>ImpACT-24M</acronym>
  <official_title>A Multicenter, Single Arm Trial to Assess Safety and Signal of Efficacy of the Ischemic Stroke System (ISS), as an Adjunct to Standard of Care in Subjects With Mild Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainsGate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainsGate</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Population:

      Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from
      onset.

      Study objectives:

        1. Identify the personal stimulation level for each patient based on physiological
           biomarkers

        2. Identify improvement in stroke symptoms during ISS treatment at the personal stimulation
           level
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Single Arm Trial to Assess Safety and Signal of Efficacy of the Ischemic
      Stroke System (ISS), as an Adjunct to Standard of Care in Subjects with Mild Acute Ischemic
      Stroke

      Study Duration:

      The expected total duration of the study for each subject is up to 10 days as follows:

      Enrollment: up to 24 hours Treatment: Implantation, 5 Days of SPG stimulation and Standard of
      care Final Visit: 7 days after enrollment

      Study Population:

      Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from
      onset.

      Study Objectives:

        1. Identify the personal stimulation level for each patient based on physiological
           biomarkers

        2. Identify improvement in stroke symptoms during ISS treatment at the personal stimulation
           level

      Study Design:

      This will be a multi-center, adjunctive to Standard of Care, single arm study, which includes
      the following steps:

        1. Screening (day 1)

        2. Implantation (day 1)

        3. Treatment and symptom assessment (days 1-5)

        4. Device Positioning and Removal (day 5)

        5. Discharge/Final Visit (day 7-10)

      Outcome Measures:

      Primary Outcome Measures:

        1. The difference in NIHSS between baseline and Day 7 vs. Historical Controls

        2. % of patients with improvement in stroke symptoms (motor and/or sensory deficits) during
           stimulation

      Additional Efficacy Outcome Measures:

        1. Existence of physiologic surrogates of the Personal Stimulation Level

        2. Improvement in stroke symptoms (motor and/or sensory deficits)

      Safety Outcome Measures:

        1. Comparative 7-day safety data between the ISS stimulation group of this study and of the
           ImpACT-24B study:

             1. Incidence of Serious Adverse Events

             2. Implantation Complications

             3. Stimulation-related Adverse Events

        2. 7-day mortality

        3. Neurological deterioration

        4. Symptomatic intracranial hemorrhage (sICH)

      Implantation Accuracy Outcome Measures:

      1. % of procedures with positive indication of reaching the sphenopalatine fossa
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">September 11, 2018</completion_date>
  <primary_completion_date type="Actual">September 11, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This will be a multi-center, adjunctive to Standard of Care, single arm study, which includes the following steps:
Screening (day 1)
Implantation (day 1)
Treatment and symptom assessment (days 1-5)
Device Positioning and Removal (day 5)
Discharge/Final Visit (day 7-10)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NIHSS Assessment</measure>
    <time_frame>Day 7</time_frame>
    <description>The difference in NIHSS between baseline and Day 7 vs. Historical Controls (the historical controls are patients in the control arm in the NINDS trial)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of patients with improvement in stroke symptoms during stimulation</measure>
    <time_frame>Day 2-5</time_frame>
    <description>Assessment of improvement in stroke symptoms (motor and/or sensory deficits) before and during stimulation at the Personal Stimulation Level, using a hand dynamometer (Baseline Hydraulic Hand Dynamometers, Fabrication Enterprises Inc, White Plains NY, USA).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Increased blood flow in Common Carotid Doppler</measure>
    <time_frame>Day 1-5</time_frame>
    <description>Increased blood flow in Common Carotid Doppler (if available) during stimulation at the Personal Stimulation Level (physiologic surrogates).</description>
  </other_outcome>
  <other_outcome>
    <measure>Existence of unilateral lacrimation, nasal secretion, and/or facial redness</measure>
    <time_frame>Day 1-5</time_frame>
    <description>Unilateral lacrimation, nasal secretion, and/or facial redness (on the stimulation side) during stimulation at the Personal Stimulation Level (physiologic surrogates).</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in stroke symptoms</measure>
    <time_frame>Day 2-5</time_frame>
    <description>Assessment of improvement in stroke symptoms (motor and/or sensory deficits) before and during stimulation at the Personal Stimulation Level, using a hand dynamometer (Baseline Hydraulic Hand Dynamometers, Fabrication Enterprises Inc, White Plains NY, USA). The investigator will measure the grasp force and pincer force before and during stimulation in the affected and non-affected sides.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Study Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ISS SPG stimulation</intervention_name>
    <description>The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).</description>
    <arm_group_label>Study Population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: ≥ 18 years and ≤ 80 years

          2. Clinical diagnosis of anterior circulation stroke

          3. Baseline NIHSS ≥ 1 and ≤ 6 or lacunar stroke of any severity

          4. Motor and/or sensory deficits

          5. Ability to initiate treatment within 24 hours from stroke onset

          6. Signed informed consent from patient him/herself or legally authorized representative
             if applicable.

             Exclusion Criteria:

          7. Neuro-imaging evidence of any intracranial hemorrhage or hemorrhagic transformation of
             brain infarct or other significant abnormality (e.g. tumor, abscess, suspect for
             subarachnoid hemorrhage).

          8. Massive stroke, defined as acute parenchymal lesion with effacement of cerebral sulci
             in over 2/3 of the MCA territory.

          9. Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an
             acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or
             Posterior Cerebral Artery territories), including but not limited to brain-stem
             findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical
             blindness.

         10. NIHSS level of consciousness score ≥ 2.

         11. Inability to communicate fluently and express symptoms

         12. Previous motor and/or sensory deficits that will eliminate the ability to identify the
             response to SPG stimulation

         13. Patients with bleeding propensity and/or one of the following: INR &gt; 1.8, prolonged
             activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count &lt; 75×109/L.

         14. Known cerebral arteriovenous malformation, cerebral aneurysm.

         15. Seizure at onset.

         16. Blood glucose concentration &lt; 60 mg/dL.

         17. Clinical suspicion of septic embolus.

         18. Uncontrolled hypertension (systolic &gt;185 mmHg and/or diastolic &gt;110 mmHg),
             demonstrated on each of three repeated measurements taken within one hour regardless
             of whether or not the patient is taking antihypertensive medications.

         19. Serious systemic infection.

         20. Women known to be pregnant or having a positive or indeterminate pregnancy test.

         21. Patients with other implanted neural stimulator/ electronic devices (pacemakers).

         22. History of SPG ablation ipsilateral to the stroke side.

         23. Any condition in the oral cavity that prevents implantation of the INS, such as
             patient is intubated, orthodontics or non-hygienic condition.

         24. Life expectancy &lt; 1 year from causes other than stroke.

         25. Participating in any other therapeutic investigational trial within the last 30 days.

         26. Known sensitivity to any medications to be used during study.

         27. Subjects who have a clinically significant or unstable medical or surgical condition
             that may preclude safe and complete study participation. Conditions may include:
             cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute
             ischemic stroke), or neoplastic diseases, as determined by medical history, physical
             examination, laboratory tests, or ECG.

         28. Subjects who, in the judgment of the investigator, are likely to be non- compliant or
             uncooperative during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kutaisi Referral Hospital</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rustavi Central Hospital</name>
      <address>
        <city>Rustavi</city>
        <zip>3700</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zugdidi Referral Hospital</name>
      <address>
        <city>Zugdidi</city>
        <zip>2100</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Mild Acute Ischemic Stroke</keyword>
  <keyword>Safety</keyword>
  <keyword>Signal of Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

